Company intelligence / Profile preview
Eyconis
Redwood City, California, United Stateseyconis.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Eyconis is developing ophthalmology assets based on the TransCon technology platform, which aims to achieve long-acting and effective delivery of multiple clinically validated biologics for retinal diseases. The company's pipeline includes at least one preclinical wet AMD medication.
- Therapeutic areas
- Ophthalmology
- Modalities
- Biologics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ascendis Pharma A/S
Beyond the preview
Go deeper on Eyconis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eyconis.